Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Mizuho from $146.00 to $175.00. They now have a "neutral" rating on the stock.
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Stifel Nicolaus from $183.00 to $188.00. They now have a "buy" rating on the stock.
Neurocrine Biosciences to Host R&D Day on December 16 [Yahoo! Finance]
Neurocrine Biosciences to Host R&D Day on December 16
Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by analysts at Royal Bank Of Canada from $160.00 to $180.00. They now have an "outperform" rating on the stock.